With around 4.7 lakh deaths around the world and 13.7 thousand deaths in India, nothing seems to be better news than the news of curative drugs for Covid-19.
Just after the Glenmark Pharmaceuticals received the sanction for the manufacturing and endorsing of the anti-viral drug against mild and moderate Covid-19 symptoms, Hetero, India’s one of the largest Pharmaceuticals company and the world’s largest producer of antiretroviral drugs, has received approval for anti-viral drug REMDESIVIR, from the Drug Controller General of India (DCGI) to treat Covid-19 patients.
The drug REMDESIVIR will be sold under the name COVIFOR and the anti-viral drug FAVIPIRAVIR that is launched by Glenmark Pharmaceuticals will be sold under the name FABIFLU.
“In the light of increasing Covid-19 cases in India, the approval of ‘COVIFOR’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country,”. Dr B Partha Saradhi Reddy, Chairman, Hetero Group of Companies said on the DCGI nod.
The company claims that they have the capability to completfulfilllfil today’s requirement of the drug.
The remedy will be used for the laboratory-confirmed cases of Covid-19 with severe symptoms, under the observation of a doctor or trained medical staff. It will be an injectible 100 mg vials, which will cost around Rs.5,000 to 6,000 per dose. As compared to this drug, Glenmark’s FABIFLU will be cheap as each tablet of 200mg costs Rs.103 and a strip of 34 tablets will cost at Rs.3500.
The medicine will be launched under the licensing agreement with Gilead Sciences Inc. to open passage the affordable treatment in low and middle-income countries.
If any of the medicines of Covid-19 proves to be an efficient drug, then it will be a great relief for the whole world especially those countries which are under a harsh attack of Covid-19